JP2023510746A5 - - Google Patents
Info
- Publication number
- JP2023510746A5 JP2023510746A5 JP2022541815A JP2022541815A JP2023510746A5 JP 2023510746 A5 JP2023510746 A5 JP 2023510746A5 JP 2022541815 A JP2022541815 A JP 2022541815A JP 2022541815 A JP2022541815 A JP 2022541815A JP 2023510746 A5 JP2023510746 A5 JP 2023510746A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- cancer
- compound
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959502P | 2020-01-10 | 2020-01-10 | |
| US62/959,502 | 2020-01-10 | ||
| PCT/US2021/012683 WO2021142247A1 (en) | 2020-01-10 | 2021-01-08 | Smarca2-vhl degraders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510746A JP2023510746A (ja) | 2023-03-15 |
| JP2023510746A5 true JP2023510746A5 (https=) | 2024-01-16 |
| JP7706456B2 JP7706456B2 (ja) | 2025-07-11 |
Family
ID=74495106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022541815A Active JP7706456B2 (ja) | 2020-01-10 | 2021-01-08 | Ｓｍａｒｃａ２－ｖｈｌ分解剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230091042A1 (https=) |
| EP (1) | EP4087658A1 (https=) |
| JP (1) | JP7706456B2 (https=) |
| AU (1) | AU2021205326A1 (https=) |
| CA (1) | CA3167166A1 (https=) |
| MX (1) | MX2022008487A (https=) |
| WO (1) | WO2021142247A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| EP4081308A4 (en) | 2019-12-23 | 2024-01-24 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| US12570650B2 (en) * | 2020-08-04 | 2026-03-10 | Aurigene Oncology Limited | 6-substituted pyridazine compounds as SMARCA2 and/or SMARCA4 degraders |
| EP4259144A4 (en) * | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| KR20240046498A (ko) | 2021-08-09 | 2024-04-09 | 제넨테크, 인크. | Brm의 조절에 사용하기 위한 페놀 유도체 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10519152B2 (en) * | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| US20190300521A1 (en) * | 2018-04-01 | 2019-10-03 | Arvinas Operations, Inc. | Brm targeting compounds and associated methods of use |
| EP3784665A4 (en) | 2018-04-26 | 2022-01-26 | Aurigene Discovery Technologies Limited | PYRIDAZINE DERIVATIVES AS SMARCA2/4 DEGRADERS |
| US11771697B2 (en) | 2018-04-30 | 2023-10-03 | Dana-Farber Cancer Institute, Inc. | Small molecule degraders of polybromo-1 (PBRM1) |
-
2021
- 2021-01-08 WO PCT/US2021/012683 patent/WO2021142247A1/en not_active Ceased
- 2021-01-08 JP JP2022541815A patent/JP7706456B2/ja active Active
- 2021-01-08 CA CA3167166A patent/CA3167166A1/en active Pending
- 2021-01-08 MX MX2022008487A patent/MX2022008487A/es unknown
- 2021-01-08 US US17/788,272 patent/US20230091042A1/en active Pending
- 2021-01-08 EP EP21702829.9A patent/EP4087658A1/en active Pending
- 2021-01-08 AU AU2021205326A patent/AU2021205326A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023510746A5 (https=) | ||
| TW384288B (en) | 5-substituted derivatives of mycophenolic acid | |
| CN111989332A (zh) | 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用 | |
| JP2010505930A5 (https=) | ||
| JP2020508310A5 (https=) | ||
| JP7205830B2 (ja) | 新規アントラニル酸系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| JP2006526590A5 (https=) | ||
| JP2020534264A5 (https=) | ||
| JP2009538327A5 (https=) | ||
| JP2006501201A5 (https=) | ||
| JPWO2018117177A1 (ja) | Ｂｒｋ阻害化合物 | |
| JP2024509981A5 (https=) | ||
| CN116113416A (zh) | 四环类衍生物、其制备方法和其医药上的用途 | |
| JP2007529426A5 (https=) | ||
| JP2017537957A (ja) | 置換されたピリジル−シクロアルキル−カルボン酸類、それらを含む組成物およびそれらの医学的使用 | |
| JP7229482B2 (ja) | 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤 | |
| WO2002006249A1 (en) | Method for producing 1-substituted-1,2,3-triazole derivative | |
| US10093609B2 (en) | TAK1 kinase inhibitors, compositions, and uses related thereto | |
| CA3167918A1 (en) | Compositions and methods for modulating cancer | |
| TW422834B (en) | Butyrate prodrugs for increasing fetal hemoglobim and promoting cell differenfiation and pharmacentical compositions comprising the same | |
| JP2017513934A5 (https=) | ||
| WO2002074296A1 (en) | Remedies for solid cancer containing hydroxamic acid derivatives as the active ingredient | |
| TW202340142A (zh) | Ｇｃｌ抑制劑 | |
| JP7644988B2 (ja) | Ｈｄａｃ阻害剤と抗ｐｄ－１抗体または抗ｐｄ－ｌ１抗体とを含む薬学組成物 | |
| JP2023002841A (ja) | 高血圧症及び／又は線維症を処置するための組成物 |